2seventy bio, Inc.

Equities

TSVT

US9013841070

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 12/06/2024 am IST			5-day change	1st Jan Change
3.93 ^USD	0.00%		-8.60%	-7.96%

10/06	Transcript : 2seventy bio, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 01:20 PM
06/06	Top Midday Decliners	MT

2Seventy Bio, Inc. Announces Resignation of Nick Leschly as CEO

September 12, 2023 at 04:30 pm IST

2seventy bio, Inc. announced that Nick Leschly has informed the Company?s Board of Directors that he intends to step down as CEO upon the Board?s identification of his successor. The Company expects that Mr. Leschly will be appointed Chairman of the Board upon this transition. The Board has retained an executive recruitment firm to assist with the search for Mr. Leschly?s successor as CEO.

Latest news about 2seventy bio, Inc.

Transcript : 2seventy bio, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 01:20 PM	10/06
Top Midday Decliners	06/06	MT
Goldman Sachs Downgrades 2seventy bio to Sell From Neutral, Adjusts Price Target to $2 From $5	06/06	MT
Earnings Flash (TSVT) 2SEVENTY BIO Reports Q1 Revenue $12.4M, vs. Street Est of $14.1M	08/05	MT
Transcript : 2seventy bio, Inc., Q1 2024 Earnings Call, May 08, 2024	08/05
2seventy bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
US FDA mandates label updates on CAR-T cancer therapies	19/04	RE
Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication	05/04	MT
Bristol Myers, 2seventy Get FDA OK for Earlier Abecma Use in Multiple Myeloma	05/04	DJ
Bristol Myers: FDA approves Abecma in multiple myeloma	05/04	CF
US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer	05/04	RE
U.S. FDA allows expanded use of Bristol Myers' cell therapy	05/04	RE
U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio?S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy	05/04	CI
Regeneron Pharmaceuticals, Inc. completed the acquiistion of R&D pipeline from 2seventy bio, Inc..	01/04	CI
Regeneron Pharmaceuticals, Inc. completed the acquiistion of R&D pipeline from 2seventy bio, Inc. for $15 million.	01/04	CI
Bristol Myers Squibb Gets EU OK for Cancer Treatment	21/03	DJ
Engine Capital Nominates Candidates to the Board of 2seventy bio	21/03	CI
2seventy bio, Inc. Announces Board Appointments	21/03	CI
Top Premarket Gainers	18/03	MT
2seventy Bio Shares Soar Premarket as FDA Panel Backs Abecma	18/03	DJ
Bristol Myers, 2seventy Bio's Cancer Treatment Wins FDA Committee Approval	16/03	DJ
FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy	16/03	CI
US FDA panel votes in favor of expanded use of Bristol Myers' CAR-T therapy	16/03	RE
2seventy Bio Shares Fall on Concerns About FDA Panel's Meeting on Abecma Gene Therapy	13/03	DJ
US FDA staff flag safety concerns from J&J, Bristol's CAR-T therapies	13/03	RE

Chart 2seventy bio, Inc.

Duration

Period

More charts

Company Profile

2seventy bio, Inc. is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The Company is focused on the commercialization and development of Abecma (idecabtagene vicleucel). Abecma is its B cell maturation antigen (BCMA)-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol Myers Squibb (BMS). ABECMA is a BCMA-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma uses a lentiviral vector (LVV), to deliver a chimeric antigen receptor (CAR), with the potential to program a patientâs own T cells to recognize the plasma cell specific BCMA, protein on the cell surface.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for 2seventy bio, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.93 USD

Average target price

9.8 USD

Spread / Average Target

+149.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
2SEVENTY BIO, INC.	-7.96%	202M
MODERNA, INC.	+49.21%	56.87B
LONZA GROUP AG	+36.30%	39.72B
IQVIA HOLDINGS INC.	-6.86%	39.27B
CELLTRION, INC.	-4.42%	28.73B
ICON PUBLIC LIMITED COMPANY	+12.00%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-18.27%	19.79B
MEDPACE HOLDINGS, INC.	+29.57%	12.28B
UNITED THERAPEUTICS CORPORATION	+25.41%	12.23B
BIO-TECHNE CORPORATION	-0.35%	12.12B

Other Biotechnology & Medical Research